Completed PHASE4 INTERVENTIONAL 2-arm NCT00775814

Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.

Double-blind, Randomized Trial to Investigate the Antihypertensive and Metabolic Effects of Candesartan in Insulin-resistant Obese Patients With a Hypertension Not Adequately Controlled by Previous ß-blocker or Calcium Channel Blocker

Sponsor: Takeda

Conditions Hypertension Obesity

Interventions Candesartan and Hydrochlorothiazide Hydrochlorothiazide (HCT)

Updated 6 times since 2017 Last updated: Aug 6, 2012 Started: Oct 31, 2006 Primary completion: Sep 30, 2008 Completion: Sep 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00775814, this PHASE4 trial focuses on Hypertension and Obesity and remains completed. Sponsored by Takeda, it has been updated 6 times since 2006, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Takeda

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bad Dürrheim, Germany , Bad Segeberg, Germany , Balingen, Germany , Berlin, Germany , Bocholt, Germany , Cologne, Germany , Deggingen, Germany , Dresden, Germany , Essen, Germany , Freital, Germany and 14 more locations